Edition:
United Kingdom

Mitsubishi Tanabe Pharma Corp (4508.T)

4508.T on Tokyo Stock Exchange

1,774JPY
7:00am BST
Change (% chg)

¥-7 (-0.39%)
Prev Close
¥1,781
Open
¥1,774
Day's High
¥1,785
Day's Low
¥1,763
Volume
675,500
Avg. Vol
1,144,864
52-wk High
¥2,707
52-wk Low
¥1,723

Latest Key Developments (Source: Significant Developments)

Health Canada Approves New Drug To Treat Patients With ALS
Thursday, 4 Oct 2018 

Oct 4 (Reuters) - HEALTH CANADA: :HEALTH CANADA APPROVES NEW DRUG TO TREAT PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS).HEALTH CANADA - WILL CONTINUE TO WORK WITH MANUFACTURER TO FACILITATE ACCESS TO EDARAVONE UNTIL AUTHORIZED DRUG IS AVAILABLE ON CANADIAN MARKET.  Full Article

R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I
Wednesday, 18 Apr 2018 

April 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Says rating outlook stable -R&I.  Full Article

Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement .  Full Article

Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Kaken Pharmaceutical Co Ltd <4521.T>:Says co signed an exclusive distribution agreement with Tai Tien Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of Mitsubishi Tanabe Pharma Corporation <<<4508.T>>>, for the topical formulation for Onychomycosis "Clenafin/Jublia" (product) in Taiwan.According to the agreement, co grants to Tai Tien the exclusive right for sales of the product in Taiwan and Tai Tien expects to launch the product in 2018.  Full Article

Mitsubishi Tanabe Pharma completes purchase of NeuroDerm
Wednesday, 18 Oct 2017 

Oct 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it completed purchase of NeuroDerm Ltd <<>>.Purchase plan was announced on July 24.  Full Article

Impatient patients turn to online 'buyers club' for new drugs

LONDON, Oct 3 Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.